Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #34 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 435,863 | 146.5 | 13.7% | 11.0% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 246,660 | 83.9 | 15.3% | 62.7% | 0.32% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 162,454 | 78.2 | 12.2% | 34.6% | 0.79% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 115,910 | 33.3 | 17.3% | 17.2% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 108,736 | 35.4 | 11.2% | -11.0% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,969 | 122.5 | 17.1% | 127.1% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 103,406 | 47.4 | 11.7% | 2.6% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 102,916 | 154.7 | 10.9% | -0.9% | — | 62 | 33 | 71 |
| Eris Lifesciences Limited (this stock) | 16,517 | 84.7 | 16.6% | -26.6% | 0.60% | 51 | 12 | 8 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 873 | 180 | 143 | ₹ |
| March 31, 2026 | 757 | 161 | 279 | ₹ |
| Dec. 31, 2025 | 807 | 145 | 109 | ₹ |
| Sept. 30, 2025 | 792 | 172 | 134 | ₹ |
| June 30, 2025 | 773 | 160 | 125 | ₹ |
| March 31, 2025 | 705 | 129 | 102 | ₹ |
| Dec. 31, 2024 | 727 | 116 | 87 | ₹ |
| Sept. 30, 2024 | 739 | 129 | 96 | ₹ |
| June 30, 2024 | 720 | 115 | 89 | ₹ |
| March 31, 2024 | 551 | 77 | 80 | ₹ |
| Dec. 31, 2023 | 486 | 116 | 101 | ₹ |
| Sept. 30, 2023 | 505 | 126 | 122 | ₹ |
| June 30, 2023 | 467 | 112 | 94 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 3,129 | 638 | 648 |
| March 31, 2025 | 2,894 | 489 | 375 |
| March 31, 2024 | 2,009 | 431 | 397 |
| March 31, 2023 | 1,685 | 405 | 374 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 538 | -369 | -314 | 297 | 241 |
| March 31, 2025 | 1,065 | -80 | -881 | 155 | 910 |
| March 31, 2024 | 486 | -1,828 | 1,380 | 129 | 357 |
| March 31, 2023 | 292 | -975 | 688 | 841 | -550 |
| March 31, 2022 | 378 | -320 | -45 | 121 | 257 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 7,366 | 3,896 | 3,889 | 1,354 | 956 | 1,540 | 2,077 | 55 | 708 | 437 |
| March 31, 2025 | 7,033 | 3,272 | 2,841 | 696 | 1,782 | 1,263 | 1,381 | 200 | 662 | 335 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
